Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection.

dc.creatorHaolla, Filipe Augusto Bettencourt
dc.creatorClasera, Carla
dc.creatorBargieri, Bruna Cunha de Alencar
dc.creatorTzelepisa, Fanny
dc.creatorVasconcelos, José Ronnie Carvalho de
dc.creatorOliveira, Gabriel Melo de
dc.creatorSilvério, Jaline Coutinho
dc.creatorMachado, Alexandre Vieira
dc.creatorVieira, Joseli Lannes
dc.creatorBruna-Romero, Oscar
dc.creatorGazzinelli, Ricardo Tostes
dc.creatorSantos, Ricardo Ribeiro dos
dc.creatorSoares, Milena Botelho Pereira
dc.creatorRodrigues, Maurício Martins
dc.date2014-12-01T18:04:06Z
dc.date2014-12-01T18:04:06Z
dc.date2009
dc.date.accessioned2023-09-26T23:02:28Z
dc.date.available2023-09-26T23:02:28Z
dc.identifierHAOLLA, F. A. et al. Strain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection. Vaccine, v. 27, n. 41, p. 5644-5653, 2009.
dc.identifier1873-2518
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/9019
dc.identifier10.1016/j.vaccine.2009.07.013
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8886149
dc.descriptionImmunisation with Amastigote Surface Protein 2 (asp-2) and trans-sialidase (ts) genes induces protective immunity in highly susceptible A/Sn mice, against infection with parasites of the Y strain of Trypanosoma cruzi. Based on immunological and biological strain variations in T. cruzi parasites, our goal was to validate our vaccination results using different parasite strains. Due to the importance of the CD8(+) T cells in protective immunity, we initially determined which strains expressed the immunodominant H-2K(k)-restricted epitope TEWETGQI. We tested eight strains, four of which elicited immune responses to this epitope (Y, G, Colombian and Colombia). We selected the Colombian and Colombia strains for our studies. A/Sn mice were immunised with different regimens using both T. cruzi genes (asp-2 and ts) simultaneously and subsequently challenged with blood trypomastigotes. Immune responses before the challenge were confirmed by the presence of specific antibodies and peptide-specific T cells. Genetic vaccination did not confer protective immunity against acute infection with a lethal dose of the Colombian strain. In contrast, we observed a drastic reduction in parasitemia and a significant increase in survival, following challenge with an otherwise lethal dose of the Colombia strain. In many surviving animals with late-stage chronic infection, we observed alterations in the heart's electrical conductivity, compared to naive mice. In summary, we concluded that immunity against T. cruzi antigens, similar to viruses and bacteria, may be strain-specific and have a negative impact on vaccine development.
dc.formatapplication/pdf
dc.languagepor
dc.publisherElsevier
dc.rightsopen access
dc.subjectTrypanosoma cruzi
dc.subjectDNA vaccine
dc.subjectAdenovirus vaccine
dc.subjectCD8
dc.subjectDoença de Chagas/prevenção & controle
dc.subjectGlicoproteínas/imunologia
dc.subjectNeuraminidase/imunologia
dc.subjectVacinas Protozoárias/imunologia
dc.subjectTrypanosoma cruzi/imunologia
dc.subjectVacinas de DNA/imunologia
dc.subjectAnticorpos Antiprotozoários/sangue
dc.subjectAnimais
dc.subjectSequência de Bases
dc.subjectReações Cruzadas
dc.subjectEpitopos de Linfócito T/imunologia
dc.subjectFeminino
dc.subjectHumanos
dc.subjectCamundongos
dc.subjectDados de Sequência Molecular
dc.subjectParasitemia/prevenção & controle
dc.subjectAlinhamento de Sequência
dc.subjectAnálise de Sobrevida
dc.subjectLinfócitos T/imunologia
dc.titleStrain-specific protective immunity following vaccination against experimental Trypanosoma cruzi infection.
dc.typeArticle


Este ítem pertenece a la siguiente institución